Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mochida Pharmaceutical receives manufacturing and marketing approval for treprostinil


Monday, 24 Mar 2014 03:15am EDT 

Mochida Pharmaceutical Co Ltd:Received manufacturing and marketing approval for an injection of 20mg, 50mg, 100mg and 200 mg (treprostinil) in Japan, for treatment of pulmonary arterial hypertension. 

Company Quote

6600.0
30.0 +0.46%
26 Dec 2014